Skip to main content

GeneTrove, Pharmacia Ink Antisense R&D Collaboration

NEW YORK, March 27 - Isis Pharmaceuticals on Wednesday said that its GeneTrove division will allow Pharmacia to use its antisense inhibitors to validate targets in genes that the biotech company selects.

Pharmacia will also license undisclosed IP from Isis' functional-genomics suite.

Terms of the deal call for Isis to design and deliver antisense inhibitors to Pharmacia. While financial terms of the deal were not disclosed, Isis will maintain the rights to develop antisense drugs to those genes, the company said.

 

Isis' functional-genomics IP suite comprises approximately 50 patents and applications, a main component of which is RNase H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.